

## Identification & Importance of Antimicrobial Susceptibility Of Non-Fermenting Gram-Negative Bacilli Among Various Clinical Specimens In A Tertiary Care Hospital

Dr. Josita Bhatia<sup>1</sup>, Dr. Bhavin Prajapati<sup>2\*</sup>, Dr. N. M. Shaikh<sup>3</sup>, Dr. Bimal Chauhan<sup>4</sup>, Dr. Tanvi Prajapati<sup>5</sup>, Dr. Hetal Odedra<sup>6</sup>, Dr. Jayshri Pethani<sup>7</sup>

<sup>1</sup>Post Graduate Resident, <sup>2</sup>Assistant Professor, <sup>3</sup>Assistant Professor,

<sup>4</sup>Assistant Professor, <sup>5</sup>Post Graduate Resident, <sup>6</sup>Tutor, <sup>7</sup>Professor and Head of the Department, Department of Microbiology, SVP Hospital, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat

\*Corresponding author: Dr Bhavin Prajapati

E-mail: [drjositabhatia@gmail.com](mailto:drjositabhatia@gmail.com)

DOI Link: 10.56018/bjkines20240611



### ABSTRACT

**Introduction:** Non-fermenting gram-negative bacilli (NFGNB) have emerged as important healthcare-associated pathogens. NFGNBs are innately resistant to many antibiotics and are known to acquire resistance by producing extended-spectrum beta-lactamase. This makes treatment of infections caused by these pathogens both difficult and expensive. Therefore, this study is undertaken with the aim of identification of NFGNB and their antimicrobial susceptibility pattern in our hospital. **Material and Method:** A total of 3233 specimens were received in the bacteriology section of the microbiology department from September 2022 to May 2023. Clinical specimens were processed for culture according to standard operating procedures. Identification and antibiotic sensitivity testing were performed by an automated: VITEK-2 compact system. **Result:** A total of 486 (15.03%) NFGNB were isolated from 3233 clinical specimens. Out of 486 isolates, *Acinetobacter baumannii* complex was the most common non-fermenter, accounting for 238 (48.97%) isolates, followed by *Pseudomonas aeruginosa* 229 (47.12%). Other significant NFGNBs isolated were: *Stenotrophomonas maltophilia* 4 (0.82%), *Myroides* spp. 4 (0.82%) etc. Vitek 2 detected carbapenem resistance in 226 (95%) of *A. baumannii* complex and 135 (59%) of *P. aeruginosa* isolates. **Conclusion:** *A. baumannii* complex and *P. aeruginosa* were the most common NFGNB isolated from wound swabs, bronchoalveolar lavage (BAL), blood, sputum, tissue, and pus. They were found to be most resistant to quinolones, carbapenems, and aminoglycosides.

**Keywords:**– Non-Fermenting Gram-Negative Bacilli, Antimicrobial susceptibility, VITEK -2

### INTRODUCTION

The non-fermentative gram-negative bacilli (NFGNB) are a group of aerobic, non-spore-forming bacilli, that either do not use carbohydrates as a source of energy or degrade them through metabolic pathways other than fermentation<sup>1</sup>. These bacteria are common inhabitants of soil and water<sup>2</sup>. Although frequently considered contaminants, most of them have emerged as important nosocomial pathogens causing opportunistic infections in immunocompromised hosts. NFGNB are known to account for about 28.26% of all bacterial isolates from a clinical microbiology laboratory<sup>3</sup>. NFGNBs causes various infections including wound infections, urinary tract infections, meningitis, pneumonia, septicemia, osteomyelitis, etc.<sup>4</sup> They are usually associated with risk factors like immunosuppression, neutropenia, mechanical ventilation, cystic fibrosis, indwelling catheters, invasive diagnostics, therapeutic procedures, prolonged hospital stay, and broad-spectrum antibiotics<sup>5</sup>. This group includes *Pseudomonas*, *Acinetobacter*, *Stenotrophomonas*, *Burkholderia*, *Alcaligenes*, *Weeksella* spp, etc. Among these *Pseudomonas aeruginosa* and *Acinetobacter baumannii* are the most isolated non-fermenters which cause pathogenic infections in humans<sup>3</sup>. Members of nonfermenting gram-negative bacteria show innate resistance to many antibiotics and are known to produce extended-spectrum beta-lactamases (ESBL) and Metallo Beta Lactamases (MBL)<sup>1</sup>. Resistance to carbapenems in non-fermenters can be intrinsic or acquired. Intrinsic resistance is seen in *S. maltophilia* while acquired Class B metallo beta-lactamases (MBL) and Class D serine carbapenamases are frequently found in *P. aeruginosa* and *Acinetobacter* spp respectively<sup>6</sup>. Multidrug resistance (MDR) exhibited by non-

fermenters poses a major clinical problem in treating infections caused by them. Therefore, early identification and institution of appropriate treatment is necessary to reduce the morbidity and mortality due to these organisms in hospitalized patients<sup>7</sup>. In recent years, the number of diagnoses of infections caused by non-fermentative bacilli has increased, largely because of a heightened awareness of the possible roles of these bacteria as pathogens rather than contaminants. Hence this study has been undertaken to isolate and speciate the nonfermenting gram-negative bacilli in various clinical samples.

## MATERIAL AND METHOD

A retrospective study was conducted in a tertiary care hospital in Ahmedabad over a period of 7 months from September 2022 to March 2023. The analysis of the reports was done in the Microbiology Department.

**Patient Enrollment:** Samples from patients visiting the Outpatient Department and admitted to the hospital were included in our study.

**Sample Collection:** All the clinical specimens received in the bacteriology lab of the microbiology department in a sterile leak-proof container for bacterial culture and sensitivity were included in the study.

Any specimens received in formalin were excluded from the study.


A total of 3233 specimens were enrolled in the study. The samples that were received were cultured on nutrient agar, blood agar, and MacConkey agar and incubated at  $35 \pm 2^\circ\text{C}$  for 18-24 hrs. Gram staining was done of pale colonies that grew on the MacConkey agar and these gram-negative bacilli were provisionally considered as Non-Fermenting Gram Negative Bacilli (NFGNB). Thereafter, identification with the VITEK-2 compact system was performed using a Vitek 2 GN card according to the manufacturer's instructions. Antibiotic susceptibility testing with the VITEK-2 compact system was performed using an AST N406 susceptibility card. AST card 406 contains amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, colistin, gentamicin, imipenem, levofloxacin, meropenem, minocycline, piperacillin/tazobactam, trimethoprim/sulfamethoxazole. The reporting of the antimicrobial susceptibility was done using CLSI M100 guidelines<sup>8,9</sup>.

## RESULTS


In total, 3233 culture specimens were received during the study period; 1069 (33.07%) cultures yielded significant pathogens and no pathogenic organisms were isolated in 2164 (66.93%) cultures. Among the 1069 (33.07%) of growth cultures, 486 (15.03%) were identified as non-fermenting gram negative bacilli, 391 (12.09%) as other gram-negative bacilli, 126 (3.90%) were identified as gram-positive cocci and 66 (2.04%) isolates were identified as *Candida* by the VITEK-2 compact system [Chart-1].

**CHART-1: DISTRIBUTION OF ISOLATES WITH RESPECT TO THE GROWTH**


- No Pathogenic Organisms [ 66.93% (2164)]
- Gram positive Cocci [3.90% (126)]
- Candida [2.04% (66)]
- Other Gram Negative Bacilli [12.09% (391)]
- Non-Fermenting Gram Negative Bacilli [15.03% (486)]




Out of 486 NFGNB, *Acinetobacter baumannii* complex 238 (48.97%) and *Pseudomonas aeruginosa* 229 (47.12%) contributed to the major number of isolates. The other non-fermenting gram-negative bacilli isolated were *Stenotrophomonas maltophilia* 4 (0.82%), *Myroides spp.* 4 (0.82%), *Sphingomonas paucimobilis* 4 (0.82%), *Achromobacter xylosoxidans ss. xylosoxidans* 2 (0.41%), *Acinetobacter lwofii* 2 (0.41%), *Elizabethkingia meningoseptica* 2 (0.41%), and *Burkholderia cepacia* Complex 1 (0.21%) [Chart-2].



Out of 486 NFGNB, 163 (33.13%) NFGNB were isolated from wound swab, 129 (26.22%) from Endotracheal tube/secretion/BAL, 49 (9.96%) from blood, 42 (8.54%) from sputum, 41 (8.33%) from urine, 24 (4.88%) from tissues, 10 (2.03%) from pus, 8 (1.63%) from fluids and rest 20 (4.07%) from other specimens [Chart 3].



Most non-fermenters were isolated from ICU [242 (49.79%)] followed by wards [183 (37.65%)] and OPD [61 (12.55%)] [Chart-4].



The antimicrobial resistance pattern of the isolated strains are shown in Table 1.

**Table 1:** Anti-microbial resistance pattern of the isolated strains in percentage

TOTAL ISOLATES	AZT	AMI	CEP	CTZ	LEV	CIP	COL	GEN	IMI	MER	MIN	PIT	TRS
<i>A. baumannii</i> Complex (n=238)	IR	84 (n=201)	89 (n=213)	86 (n=204)	79 (n=187)	94 (n=224)	0 (n=0)	92 (n=218)	95 (n=226)	94 (n=224)	35 (n=84)	95 (n=225)	92 (n=218)
<i>P. aeruginosa</i> (n=229)	9 (n=20)	59 (n=134)	55 (n=125)	64 (n=147)	72 (n=165)	71 (n=162)	3 (n=7)	62 (n=143)	55 (n=125)	59 (n=135)	IR	63 (n=144)	IR
<i>S. maltophilia</i> (n=4)	IR	IR	NT	NT	50 (n=2)	NT	NT	IR	IR	IR	25 (n=1)	IR	75 (n=3)
<i>Myroides spp.</i> (n=4)	100 (n=4)	100 (n=4)	100 (n=4)	100 (n=4)	100 (n=4)	100 (n=4)	NT	100 (n=4)	100 (n=4)	100 (n=4)	0 (n=0)	100 (n=4)	100 (n=4)
<i>S. paucimobilis</i> (n=4)	75 (n=3)	25 (n=1)	25 (n=1)	50 (n=2)	25 (n=1)	75 (n=3)	NT	50 (n=2)	50 (n=2)	50 (n=2)	0 (n=0)	25 (n=1)	25 (n=1)
<i>A. xylosoxidans</i> ss. <i>xylosoxidans</i> (n=2)	100 (n=2)	50 (n=1)	50 (n=1)	0 (n=0)	0 (n=0)	100 (n=2)	NT	50 (n=2)	0 (n=0)	0 (n=0)	0 (n=0)	0 (n=0)	100 (n=2)
<i>A. lwoffii</i> (n=2)	IR	100 (n=2)	100 (n=2)	100 (n=2)	50 (n=1)	50 (n=1)	0 (n=0)	50 (n=1)	100 (n=2)	100 (n=2)	50 (n=1)	100 (n=2)	100 (n=2)
<i>E. meningoseptica</i> (n=2)	50 (n=1)	100 (n=2)	100 (n=2)	100 (n=2)	50 (n=1)	100 (n=2)	NT	100 (n=2)	100 (n=2)	100 (n=2)	50 (n=1)	100 (n=2)	100 (n=2)
<i>B. cepacia</i> Complex (n=1)	NT	NT	NT	100 (n=1)	100 (n=1)	NT	IR	NT	NT	0 (n=0)	0 (n=0)	NT	100 (n=1)

Abbreviation of antibiotic: EUCAST System for Antimicrobial Abbreviations<sup>10</sup>. AZT- Aztreonam, AMI- Amikacin, CEP- Cefepime, CTZ- Ceftazidime, LEV- Levofloxacin, CIP- Ciprofloxacin, COL- Colistin, GEN- Gentamicin, IMI- Imipenem, MER- Meropenem, MIN- Minocycline, PIT- Piperacillin-tazobactam, TRS- Trimethoprim-sulfamethoxazole. Abbreviations: IR:- Intrinsic resistance; NT:- Not tested

Vitek 2 data was entered into WHONET which detected Multi-Drug Resistant (MDR), Possible Pan-Drug Resistant (PDR), and Possible Extreme Drug Resistant (XDR) isolates. 403 (82.92%) of 486 NFGNB were found to be MDR, out of which 229 (47.12%) isolates were *A. baumannii* complex, 170 (34.98%) isolates were *P. aeruginosa* isolates, 2 (0.411%) were *A. lwofii*, 1 (0.21%) was *Elizabethkingia meningoseptica* and 1 (0.21%) was *Sphingomonas paucimobilis*. These 403 NFGNB were susceptible to colistin only. 178 (30.25%) of the total 486 isolates were found to be possible XDR with 135 (27.78%) isolates of *A. baumannii* complex, 42 (8.64%) isolates of *P. aeruginosa*, and 1 (0.21%) isolate of *Acinetobacter lwofii*. Possible PDR was found to be in 214 (44.03%) of total 486 isolates; 116 (23.86%) *A. baumannii* complex, 95 (19.54%) *P. aeruginosa*, and 1 (0.21%) isolate each of *Sphingomonas paucimobilis*, *Acinetobacter lwofii*, *Elizabethkingia meningoseptica*.

Table 2 shows the carbapenem resistant *A. baumannii* complex isolates and *P. aeruginosa* isolates.

**Table 2:** Carbapenem resistant *A. baumannii* complex and *P. aeruginosa* isolates.

<i>A. baumannii</i> Isolates (%)	<i>P. aeruginosa</i> Isolates (%)
95 (n=225)	59 (n=135)

## DISCUSSION

Non-fermenting Gram-Negative bacilli (NFGNB) are being isolated with increasing frequency from clinical specimens and treatment failure due to their multidrug resistance in recent years. 15.03% (486) clinical isolates of non-fermenting Gram-negative bacilli isolated from various clinical samples like pus, urine, endotracheal aspirates, blood, sputum, body fluids, and were evaluated for their role in infections in hospitalized patients including the characteristics of their drug resistance. A similar isolation rate (14.6%) was seen in a study done by Shweta Sharma et al<sup>11</sup>. Less isolation rate (7.59%) was reported in a study by Suhani Gondha et al<sup>12</sup> in 2022. In this study, the maximum number of isolates were from intensive care units (49.79%) followed by wards (37.65%) and OPDs (12.55%).

In the present study, the commonest isolates were *Acinetobacter baumannii* complex 48.97% (238) followed by *Pseudomonas aeruginosa* 47.12% (229), *Stenotrophomonas maltophilia* 0.82% (4), *Myroides spp.* 0.82% (4), *Sphingomonas paucimobilis* 0.82% (4), *Achromobacter xylosoxidans ss. xylosoxidans* 0.41% (2), *Acinetobacter lwofii* 0.41% (2), *Elizabethkingia meningoseptica* 0.41% (2), and *Burkholderia cepacia* Complex 0.21% (1).

On comparison with the similar study done by Anu Sharma et al.<sup>13</sup>, it was found that the highest number of non-fermentative gram-negative bacilli isolated was *Pseudomonas aeruginosa* with the rate of isolation (56%) different than this study (47.12%). Study done by Yadav et al<sup>14</sup> showed 44% isolation rate of *Acinetobacter baumannii* complex.

In a study done by Ndzabandzaba S et al<sup>15</sup>, *Acinetobacter baumannii* complex (20.4%) was the third most commonly isolated organism from ICUs after *Burkholderia cepacia* (24%) and *S. maltophilia* (23.3%). In the present study, *Acinetobacter baumannii* complex (61.98%) was the most commonly isolated NFGNB followed by *Pseudomonas aeruginosa* (33.47%).

Because of the high intrinsic resistance of different NFGNBs to different antimicrobial agents, the value of proper identification and resistance testing is foremost important in each setup to guide the appropriate selection of empiric therapy. The antimicrobial susceptibility pattern of *A. baumannii* complex showed resistance to imipenem (95%), meropenem (95%), and piperacillin/tazobactam (95%) followed by ciprofloxacin (94%), gentamicin (92%), trimethoprim-sulfamethoxazole (92%), cefepime (89%), ceftazidime (86%), and amikacin (84%). *P. aeruginosa* showed resistance to ciprofloxacin (72%), levofloxacin (72%) followed by ceftazidime (64%), gentamicin (63%), piperacillin/tazobactam (63%), meropenem (59%), amikacin (59%), imipenem (55%) and cefepime (55%).

NFGNB, especially *P. aeruginosa* and *A. baumannii*, are remarkably adept at adapting to environmental pressures, upregulating their intrinsic resistance mechanisms, and acquiring and transferring drug-resistance genes through mobile genetic elements such as plasmids and transposons<sup>16</sup>. As a result, these bacteria exhibit an alarmingly high overall drug resistance prevalence rate against diverse categories of drugs. The acquired drug resistance genes enable bacteria to produce beta-lactamase enzymes, particularly ESBLs, which confer resistance to most beta-lactam antibiotics. Furthermore, ESBL-producing Gram-negative bacteria have been identified to possess additional

resistance mechanisms to other categories of antimicrobials, including phenicol's, sulfonamides, fluoroquinolones, tetracyclines, and aminoglycosides.

Multidrug resistance is a major problem with non-fermenting gram-negative bacilli and so the infections caused by them are very difficult to treat. Polymyxins are the last resort antimicrobial drug class with consistent activity against multidrug-resistant strains of non-fermenters.

## CONCLUSION

Non-fermenting gram-negative bacteria are a group of microorganisms that pose significant challenges in clinical microbiology. These bacteria, which include members of the *Acinetobacter* group, are commonly found in various environments such as human skin, soil, water, and sewage. They are opportunistic pathogens and have the potential to cause nosocomial infections, making them a concern for healthcare providers. The clinical importance of these non-fermenting gram-negative bacteria is still unknown but these studies should raise awareness among physicians. In recent years, there has been a global increase in infections caused by gram-negative bacteria, with gram-negative organisms often surpassing gram-positive infections in prevalence in various healthcare settings. This trend highlights the need for effective strategies to detect and manage infections caused by non-fermenting gram-negative bacteria. Given their resistance to antibiotics and ability to cause infections in different body sites, including the lungs, abdomen, and incision sites, healthcare providers must be vigilant and proactive in identifying and treating these infections. The Infectious Diseases Society of America recognizes non-fermenting gram-negative bacteria as some of the most problematic pathogens in the field of infectious diseases. These bacteria present unique challenges due to their ability to resist multiple antibiotics, including some of the most commonly used drugs in clinical settings. Therefore, healthcare providers must stay updated on the latest research and clinical guidelines surrounding non-fermenting gram-negative bacteria. Efforts must be made to improve detection methods and develop effective strategies for managing infections caused by these bacteria.

## REFERENCES

1. Koneman EW, Allen SD. Colour atlas and Text book of diagnostic Microbiology, 7th Ed, Philadelphia: Lippincott-Williams & Wilkins Publishers; 2016.
2. Gokhale S, Metgud SC. Characterization and antibiotic sensitivity pattern of nonfermenting gram negative bacilli from various clinical samples in a tertiary care hospital, Belgaum. J Pharm Biomed Sci. 2012; 17(17): 1-5.
3. Kirtilaxmi KB, Padmavathy M, Malini J, Navaneeth BV. Prevalence of non-fermenting Gram-negative bacilli and their in vitro susceptibility pattern at a tertiary care teaching hospital. J Sci Soc. 2014; 41(3): 162-6.
4. Nagoba BS, Deshmukh SR, Ulka GG, Gude et al. In vitro susceptibility of *Pseudomonas aeruginosa* to different antibiotics. Indian J Med Microbiol 1997; 15: 185-6.
5. Mishra B, Bhujwala RA, Srinivasa, Non fermenters in human infections. Indian J Med Res 1986 Jun; 83(1): 561-6.
6. Felipe Fernandez, Luis Martinez, M Carman, Juan A. Relationship between  $\beta$ -lactamase production, Outer membrane proteins and Penicillin binding proteins profiles on the activity of Carbapenems against clinical isolates of *A. baumannii*. J. Antimicrob. Chemo. 2003; 51(3): 565-74.
7. Vikas Manchanda, Sinha Sanchalta and NPSingh. Multi Drug Resistant *Acinetobacter*. J Glob Infect Dis 2010; 2(3): 291-304.
8. CLSI M100 2022 Ed. 32
9. CLSI M100 2023 Ed 33
10. EUCAST System for Antimicrobial Abbreviations
11. Sharma S, Pujari S, Sharma AK. Isolation of non-fermenting Gram negative bacteria in respiratory tract infections. IP Int J Med Microbiol Trop Dis 2020; 6(3): 184-187.
12. Suhani Gondha, Ghanshyam Kavathia, Arpita Bhattacharya (2022). A Study of Isolation, Identification & Antibiotic Susceptibility Pattern of Non-Fermenting Gram Negative Bacilli Isolated From Various Clinical Samples at Tertiary Care Hospital Rajkot, Gujarat, Western India. Saudi J Pathol Microbiol, 7(6): 233-239.
13. Dr. Anu sharma, Dr K.V. Ingole, Dr Abhilasha Belpatre, Identification of non-fermenter gram negative bacilli (NFGNB) and its antibiotic susceptibility pattern in various clinical isolates at a tertiary care hospital., PARIPEX INDIAN JOURNAL OF RESEARCH: Volume-7 | Issue-9 | September-2018

14. Yadav, S.K., Bhujel, R., Mishra, S.K. et al. Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal. BMC Res Notes 13, 319 (2020). <https://doi.org/10.1186/s13104-020-05163-6>
15. Ndzabandzaba S, Mothibi L, von Knorring N. Non-fermenter Gram-negative bacilli at a tertiary hospital, South Africa. S Afr J Infect Dis. 2023 Nov 20;38(1):538. doi: 10.4102/sajid.v38i1.538. PMID: 38058659; PMCID: PMC10697235.
16. Bitew A. High Prevalence of Multi-Drug Resistance and Extended Spectrum Beta Lactamase Production in Non-Fermenting Gram-Negative Bacilli in Ethiopia. Infect Dis (Auckl). 2019 Nov 5;12:1178633719884951. doi: 10.1177/1178633719884951. PMID: 31723320; PMCID: PMC6836305.